PRO 156

Drug Profile

PRO 156

Alternative Names: PRO-156

Latest Information Update: 14 Jul 2014

Price : $50

At a glance

  • Originator Laboratorios Sophia
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Eye disorders

Most Recent Events

  • 01 Dec 2013 Laboratorios Sophia completes a phase I trial in Eye disorders in Mexico (NCT01871077)
  • 01 Sep 2013 Phase-I clinical trials in Eye disorders in Mexico (Ophthalmic)
  • 04 Jun 2013 Preclinical trials in Eye disorders in Mexico (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top